Uniqure

Yahoo Finance • 6 days ago

Advanced Viral Delivery Systems Revolutionizing Gene Therapy for Neurological Disorders

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy on Neurological Diseases Market Report 2025" has been added to ResearchAndMarkets.com's offering. The gene therapy on neurological diseases market size has grown rapidly in... Full story

Yahoo Finance • 13 days ago

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

LEXINGTON, Mass. and AMSTERDAM, Sept. 29, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its... Full story

Yahoo Finance • 16 days ago

uniQure announces pricing of upsized $300M public offering

* uniQure N.V. (NASDAQ:QURE [https://seekingalpha.com/symbol/QURE]) announced on Thursday the pricing of its previously announced underwritten public offering [https://seekingalpha.com/pr/20245492-uniqure-announces-pricing-of-upsized-300... Full story

Yahoo Finance • 16 days ago

uniQure Announces Pricing of Upsized $300 Million Public Offering

LEXINGTON, Mass. and AMSTERDAM, Sept. 25, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its... Full story

Yahoo Finance • 17 days ago

Stocks making the biggest moves midday: Mirion Technologies, Freeport-McMoRan, CarMax & more

Check out the companies making the biggest moves midday: Mirion Technologies — The radiation detection name fell more than 8% after it announced a common stock offering of $300 million. Mirion is also selling $250 million in convertible bo... Full story

Yahoo Finance • 17 days ago

Uniqure (QURE) Soars 275% on Stellar Clinical Trial for Huntington’s Disease

We recently published 10 Stocks Crushing Wall Street, AI Stocks Dominate. Uniqure NV (NASDAQ:QURE) is one of the top performers on Tuesday. Shares of Uniqure NV soared by as much as 275 percent on Wednesday to hit a new all-time high as i... Full story

Yahoo Finance • 17 days ago

Stocks making the biggest premarket moves: Intel, Oracle, Lithium Americas, Opendoor and more

Check out the companies making the biggest moves in premarket trading: Oracle — The database software company fell 3% as worries around the AI trade continue to drag the stock lower. Rothschild & Co Redburn initiated coverage of Oracle wit... Full story

Yahoo Finance • 18 days ago

uniQure Announces $200 Million Proposed Public Offering

LEXINGTON, Mass. and AMSTERDAM, Sept. 24, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenc... Full story

Yahoo Finance • 18 days ago

uniQure succeeds in pivotal trial for one-time Huntington’s disease therapy

Hailshadow uniQure (NASDAQ:QURE [https://seekingalpha.com/symbol/QURE]) announced on Wednesday that its one-time gene therapy AMT-130 reached the main goals in a pivotal Phase 2/3 trial for patients with Huntington’s disease, a rare neuro... Full story

Yahoo Finance • 18 days ago

uniQure announces refinancing of $50M debt and secures additional $125M in non-dilutive funding

* uniQure (NASDAQ:QURE [https://seekingalpha.com/symbol/QURE]) said on Wednesday that it entered into a $175M non-dilutive senior secured term loan facility [https://seekingalpha.com/pr/20242480-uniqure-announces-refinancing-of-existing-... Full story

Yahoo Finance • 18 days ago

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding

~ Term of current $50 million debt outstanding extended from January 2027 to October 2030 ~ ~ Additional $100 million available subject to regulatory and financial milestones ~ ~ Additional $25 million available subject to Hercules’ appr... Full story

Yahoo Finance • 18 days ago

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external control ~ ~ High-dose AMT-130 also demon... Full story

Yahoo Finance • last month

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

~ All patients in the first cohort achieved between 27- to 208-fold increases in α-Gal A activity relative to mean normal level ~ ~ All patients in first cohort discontinued enzyme replacement therapy ~ ~ Preliminary data show AMT-191 ha... Full story

Yahoo Finance • 2 months ago

UniQure outlines planned BLA submission for AMT-130 in Q1 2026 amid regulatory alignment and pipeline momentum

Earnings Call Insights: uniQure N.V. (QURE) Q2 2025 MANAGEMENT VIEW * CEO Matthew Kapusta highlighted that "the first half of 2025 has been tremendously productive for the company as we advance AMT-130 towards potentially becoming the... Full story

Yahoo Finance • 2 months ago

uniQure NV (NASDAQ:QURE) Posts Q2 2025 Earnings: EPS Beat Offsets Revenue Miss as Regulatory Progress Boosts Shares

UNIQURE NV (NASDAQ:QURE [https://www.chartmill.com/stock/quote/QURE]) REPORTS Q2 2025 EARNINGS: MIXED RESULTS AMID REGULATORY PROGRESS uniQure NV released its second-quarter 2025 financial results, revealing a mixed performance relative t... Full story

Yahoo Finance • 2 months ago

uniQure gives mixed Q2 results

* uniQure press release [https://seekingalpha.com/pr/20180491-uniqure-announces-second-quarter-2025-financial-results-and-highlights-of-recent-company] (NASDAQ:QURE [https://seekingalpha.com/symbol/QURE]): Q2 GAAP EPS of -$0.69 beats by... Full story

Yahoo Finance • 2 months ago

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

~ Achieved alignment with the FDA on the AMT-130 statistical analysis plan and CMC requirements to support a planned BLA submission in the first quarter of 2026; ~ Company expects to present AMT-130 topline three-year data in September 20... Full story

Yahoo Finance • 2 months ago

uniQure Q2 2025 Earnings Preview

* uniQure (NASDAQ:QURE [https://seekingalpha.com/symbol/QURE]) is scheduled to announce Q2 earnings results on Tuesday, July 29th, before market open. * The consensus EPS Estimate is -$0.88 [https://seekingalpha.com/symbol/QURE/earning... Full story

Yahoo Finance • 3 months ago

uniQure to Announce Second Quarter 2025 Financial Results

LEXINGTON, Mass. and AMSTERDAM, July 22, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report second quarter 2025 finan... Full story

Yahoo Finance • 4 months ago

uniQure N.V. chief legal officer Potts sells $70k in shares

uniQure N.V. (NASDAQ:QURE) Chief Legal Officer Jeannette Potts sold 4,670 ordinary shares of the company on June 16, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average... Full story